Affymetrix Announces Court Order Directing Dismissal of Illumina Patent Infringement Lawsuits

Affymetrix, Inc. (NASDAQ:AFFX) (the “Company”) today announced that the U.S. District Court for the Western District of Wisconsin (the “Court”) has granted the company’s motion for summary judgment that Affymetrix does not infringe the patents held by Illumina, Inc. (NASDAQ: ILMN), and has directed that the patent infringement lawsuits brought against the company by Illumina regarding U.S. Patent Nos. 7,510,841 and 7,612,020 be dismissed and the cases closed.

“We are pleased with the Court’s ruling, which confirms our position that Illumina’s lawsuits were without merit,” said Rick Runkel, Affymetrix’s Executive Vice President, General Counsel and Secretary. “As a biotechnology company that invests significant time, resources and expertise in R&D, we are committed to conducting our business with the utmost integrity and believe that the Court’s ruling underscores this commitment.”

About Affymetrix

Affymetrix technology is used by the world's top pharmaceutical, diagnostic, and biotechnology companies, as well as leading academic, government, and nonprofit research institutes. More than 1,900 systems have been shipped around the world and more than 22,000 peer-reviewed papers have been published using the technology.

Affymetrix is headquartered in Santa Clara, Calif., and has manufacturing facilities in Cleveland, Ohio, and Singapore. The company has about 1,000 employees worldwide and maintains sales and distribution operations across Europe and Asia. For more information about Affymetrix, please visit http://www.affymetrix.com.